Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
12 Jan 2020
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.

Maternal history of eating disorders affects daughters’ risks

06 Oct 2019

Girls born to mothers with eating disorders (EDs) are significantly more prone to developing ED symptoms and receiving relevant treatment, a recent study has found.

Drawing from the Growing Up Today Study, researchers obtained relevant data on 3,649 females (mean age at baseline, 11.6±1.6 years), of whom 28.3 percent had shown symptoms of any ED. Among the EDs examined were anorexia nervosa, bulimia nervosa, binge ED, and other specified feeding or ED (OSFED) in at least 1 year; 4.8 percent received professional diagnoses.

Participants whose mothers had had EDs were significantly more likely to meet the criteria for being positive for symptoms of bulimia nervosa (adjusted odds ratio [OR], 2.82, 95 percent CI, 1.44–5.54), binge ED (adjusted OR, 1.77, 1.10–2.83) and OSFED (adjusted OR, 1.77, 1.28–2.46). No such effect was reported for anorexia nervosa.

Conversely, 10.2 percent of the women who reported undergoing treatment for ED had mothers with a history of the disease, as compared to only 4.5 percent of those who were not receiving treatment (p<0.001). Particularly, among the participants who fulfilled the criteria of any ED or OSFED, those with maternal ED histories were more than twice as likely to receive treatment.

Treatment rates for anorexia nervosa, bulimia nervosa, binge ED and OSFED were 20.7 percent, 46.4 percent, 12.1 percent and 13.1 percent, respectively. Seventy-five percent of participants who had been professionally diagnosed sought treatment.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
12 Jan 2020
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.